Apogem Capital’s Alkermes ALKS Stock Holding History

Apogem Capital’s Portfolio ALKS Stock Details ALKS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-35,751	Closed	-$798K	–	5
2022 Q3	$798K	Buy	+35,751	New	+$930K	0.79%	35

Other funds holding ALKS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HJGA

Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return

CWM

CIBC World Markets New York $20.8B AUM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Apogem Capital's ALKS Position: Q4 2022 in Review

Apogem Capital sold out of Alkermes (ALKS) in Q4 2022, closing a stake of 35,751 shares — an estimated $798K sold.

Apogem Capital first reported a position in ALKS in Q3 2022 and held it in 1 quarter. The position peaked at $798K in Q3 2022. 278 funds tracked by Wall St. Rank hold ALKS as of Q4 2022.

Apogem Capital reported no remaining Alkermes position as of Q4 2022 after selling out during the quarter.
Apogem Capital sold 35,751 Alkermes shares in Q4 2022, an estimated $798K.
Apogem Capital first reported a position in Alkermes in Q3 2022 and held it in 1 quarter.
Apogem Capital's Alkermes position peaked at $798K in Q3 2022.
278 funds tracked by Wall St. Rank held Alkermes as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.